Search results
Results from the WOW.Com Content Network
Xanomeline/trospium chloride, sold under the brand name Cobenfy, is a fixed-dose combination medication used for the treatment of schizophrenia. [1] It contains xanomeline , a muscarinic agonist ; and trospium chloride , a muscarinic antagonist . [ 1 ]
The lack of a warning sent Bristol Myers' shares up 6.3% at $53.28 in premarket trading on Friday. Bristol Myers obtained drug Cobenfy, also known as KarXT, through its $14 billion takeover of ...
Bristol and partner Pfizer's blood thinner Eliquis was also on the list of 10 drugs that will be subject ... Bristol Myers Squibb said on Thursday it plans to double the number of treatments it is ...
Main Menu. News. News
Bristol-Myers Squibb logo from 1989 to 2020 The company has a number of ... schizophrenia drugs named Cobenfy which is the first novel type of treatment for the ...
Xanomeline/trospium, sold under the brand name Cobenfy, is an approved combination drug used in the treatment of schizophrenia. [ 6 ] [ 7 ] Trospium chloride is a peripherally selective non-selective muscarinic antagonist to quell peripheral muscarinic agonist-dependent side effects.
Image source: The Motley Fool. Bristol Myers Squibb (NYSE: BMY) Q3 2024 Earnings Call Oct 31, 2024, 8:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants
Retrieved from "https://en.wikipedia.org/w/index.php?title=Bristol-Myers_Squibb_Company&oldid=971830359"